share_log

Transcode Therapeutics | 10-Q: Q2 2024 Earnings Report

Transcode Therapeutics | 10-Q: Q2 2024 Earnings Report

Transcode Therapeutics | 10-Q：2024財年二季報
美股SEC公告 ·  2024/08/14 13:51

Moomoo AI 已提取核心訊息

TransCode Therapeutics reported a net loss of $5.2 million for Q2 2024, compared to a $4.3 million loss in Q2 2023. Research and development expenses increased by $116,000 to $3.1 million, while general and administrative expenses decreased by $125,000 to $2.0 million. The company had $3.4 million in cash as of June 30, 2024.The company achieved significant clinical milestones, including receiving FDA authorization to proceed with a Phase I/II clinical trial for its lead candidate TTX-MC138. Preliminary results from its Phase 0 trial showed successful delivery of TTX-MC138 to metastatic lesions and significant inhibition of target miRNA-10b. The company entered collaborations with Debiopharm and another biotechnology company to expand its therapeutic platform.TransCode faces near-term financial challenges, with current cash expected to fund operations only into late 2024. The company received notice from Nasdaq regarding non-compliance with the minimum bid price requirement and must appeal by August 20, 2024, to maintain listing. Management is considering cost reduction strategies and additional financing options to sustain operations.
TransCode Therapeutics reported a net loss of $5.2 million for Q2 2024, compared to a $4.3 million loss in Q2 2023. Research and development expenses increased by $116,000 to $3.1 million, while general and administrative expenses decreased by $125,000 to $2.0 million. The company had $3.4 million in cash as of June 30, 2024.The company achieved significant clinical milestones, including receiving FDA authorization to proceed with a Phase I/II clinical trial for its lead candidate TTX-MC138. Preliminary results from its Phase 0 trial showed successful delivery of TTX-MC138 to metastatic lesions and significant inhibition of target miRNA-10b. The company entered collaborations with Debiopharm and another biotechnology company to expand its therapeutic platform.TransCode faces near-term financial challenges, with current cash expected to fund operations only into late 2024. The company received notice from Nasdaq regarding non-compliance with the minimum bid price requirement and must appeal by August 20, 2024, to maintain listing. Management is considering cost reduction strategies and additional financing options to sustain operations.
TransCode Therapeutics報告2024年第二季度淨虧損520萬美元，而2023年第二季度則虧損430萬美元。研發支出增加了116,000美元，總額達到310萬美元，而一般和行政開支減少了125,000美元，降至200萬美元。截止到2024年6月30日，公司現金餘額爲340萬美元。公司實現了顯著的臨牀里程碑，包括獲得FDA授權繼續進行其主要候選藥物TTX-MC138的I/II期臨牀試驗。來自其I期臨牀試驗的初步結果顯示成功將TTX-MC138遞送至轉移性病竈，並顯著抑制了目標miRNA-100億。公司與Debiopharm及另一家生物技術公司建立了合作關係，以擴展其治療平台。TransCode面臨短期財務挑戰，目前現金預計只能維持運營到2024年底。公司收到了納斯達克關於未能遵守最低買盤價格要求的通知，並必須在2024年8月20日之前上訴以維持上市。管理層正在考慮降低成本的策略和額外的融資方案以維持運營。
TransCode Therapeutics報告2024年第二季度淨虧損520萬美元，而2023年第二季度則虧損430萬美元。研發支出增加了116,000美元，總額達到310萬美元，而一般和行政開支減少了125,000美元，降至200萬美元。截止到2024年6月30日，公司現金餘額爲340萬美元。公司實現了顯著的臨牀里程碑，包括獲得FDA授權繼續進行其主要候選藥物TTX-MC138的I/II期臨牀試驗。來自其I期臨牀試驗的初步結果顯示成功將TTX-MC138遞送至轉移性病竈，並顯著抑制了目標miRNA-100億。公司與Debiopharm及另一家生物技術公司建立了合作關係，以擴展其治療平台。TransCode面臨短期財務挑戰，目前現金預計只能維持運營到2024年底。公司收到了納斯達克關於未能遵守最低買盤價格要求的通知，並必須在2024年8月20日之前上訴以維持上市。管理層正在考慮降低成本的策略和額外的融資方案以維持運營。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    特斯拉績後巨震，後市你怎麽看？
    特斯拉2024年Q4營收257.1億美元，同比增長2%，不及預期。Cybercab計劃2026年投產，預計車輛業務將於2025年恢復增長。面對特朗普回歸，特斯拉股價能否在2025年繼續攀升？
    TSLA收益預覽：猜測開盤價贏取獎勵！